Study guide
13.2 Smart Infusion Pumps & Dose Error Reduction Systems (DERS)
Board Certified Pediatric Pharmacy Specialist BCPPS
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Pediatric Patient Characteristics — Growth, Anthropometrics & Perinatal Exposure
1.1 Normal Growth, Development & Growth-Chart Interpretation 1.2 Anthropometrics: Body Surface Area, Dosing Weights & Maximum-Dose Caps 1.3 Medication Use in Pregnancy and Lactation
2 Chapter 2: Developmental Pharmacokinetics & Neonatal Principles
2.1 Developmental PK: Absorption, Distribution & Body Water Dynamics 2.2 Hepatic Metabolism & CYP/UGT Isoenzyme Maturation 2.3 Renal Function Maturation & Glomerular Filtration Development
3 Chapter 3: Neonatal Critical Care & Prematurity Complications
3.1 Neonatal Sepsis & Meningitis (Early-Onset vs Late-Onset Sepsis) 3.2 Respiratory Distress Syndrome, Surfactant & Bronchopulmonary Dysplasia 3.3 Patent Ductus Arteriosus, Apnea of Prematurity & Necrotizing Enterocolitis
4 Chapter 4: Pediatric Infectious Diseases — Respiratory & ENT Infections
4.1 Acute Otitis Media, Sinusitis & Pharyngitis 4.2 Pediatric Community-Acquired Pneumonia & Parapneumonic Effusion 4.3 Bronchiolitis, RSV Prevention (Nirsevimab, Clesrovimab, Palivizumab) & Viral Lower Respiratory Infections
5 Chapter 5: Pediatric Infectious Diseases — Systemic, Bone & CNS Infections
5.1 Pediatric Meningitis, Encephalitis & Brain Abscess 5.2 Skin, Soft Tissue, Osteomyelitis & Septic Arthritis 5.3 Pediatric Sepsis, Febrile Neutropenia & Central Line-Associated Bloodstream Infections
6 Chapter 6: Pediatric Pulmonary Medicine — Asthma & Status Asthmaticus
6.1 Chronic Pediatric Asthma Assessment & Stepwise Outpatient Pharmacotherapy 6.2 Status Asthmaticus & Acute Exacerbation Pharmacotherapy in ED/PICU 6.3 Aerosol Drug Delivery, Spacers & Specialized Inhalation Devices
7 Chapter 7: Cystic Fibrosis & Chronic Pediatric Respiratory Disorders
7.1 Pathophysiology, Diagnosis & Airway Clearance in Cystic Fibrosis 7.2 CFTR Modulator Therapies & Monitoring 7.3 CF Pulmonary Exacerbations, Chronic Infection Management & Comorbidities
8 Chapter 8: Pediatric Cardiology & Hemodynamics
8.1 Congenital Heart Defects & Ductal-Dependent Lesions 8.2 Pediatric Heart Failure & Cardiomyopathies 8.3 Pediatric Arrhythmias & Syncope Management
9 Chapter 9: Pediatric Resuscitation, Shock & Critical Care Support
9.1 PALS Resuscitation Algorithms & Cardiac Arrest Pharmacotherapy 9.2 Pediatric Shock States & Vasoactive / Inotropic Selection 9.3 Extracorporeal Membrane Oxygenation (ECMO) & Critical Care PK
10 Chapter 10: Pediatric Neurology & Psychiatric Disorders
10.1 Neonatal Seizures & Pediatric Status Epilepticus 10.2 Pediatric Epilepsy Syndromes & Maintenance Anticonvulsants 10.3 Attention-Deficit/Hyperactivity Disorder (ADHD) & Pediatric Mood Disorders
11 Chapter 11: Pediatric Endocrinology & Metabolic Disorders
11.1 Pediatric Type 1 Diabetes Mellitus Management & Insulin Technologies 11.2 Diabetic Ketoacidosis (DKA) Protocols & Cerebral Edema Prevention 11.3 Growth Hormone, Pubertal Disorders & Congenital Adrenal Hyperplasia
12 Chapter 12: Pediatric Hematology, Oncology & Supportive Care
12.1 Sickle Cell Disease: Vaso-occlusive Crises & Disease-Modifying Therapies 12.2 Pediatric Acute Lymphoblastic Leukemia (ALL) & Chemotherapy Toxicities 12.3 Oncologic Emergencies: Tumor Lysis Syndrome & Supportive Care
13 Chapter 13: Pediatric Medication Safety & Error Prevention
13.1 High-Alert Pediatric Medications & Ten-Fold Dosing Calculation Traps 13.2 Smart Infusion Pumps & Dose Error Reduction Systems (DERS) 13.3 Medication Reconciliation & Pediatric Care Transitions
14 Chapter 14: Pediatric Compounding & Formulation Technology
14.1 Non-Sterile Compounding (USP <795>) & Liquid Formulations 14.2 Sterile Compounding (USP <797>) & Micro-Dosing Considerations 14.3 Hazardous Drug Handling (USP <800>) & Excipient Toxicities
15 Chapter 15: Fluids, Electrolytes & Clinical Nutrition Support
15.1 Fluid Requirements, Dehydration Assessment & Maintenance Therapy 15.2 Electrolyte Disturbances: Sodium, Potassium & Calcium Management 15.3 Pediatric & Neonatal Parenteral Nutrition (PN) Formulation
16 Chapter 16: Pediatric Pain Management, Sedation & Delirium
16.1 Age-Specific Pain Assessment Tools & Analgesic Selection 16.2 Procedural Sedation & Rapid Sequence Intubation in Children 16.3 PICU Delirium, Iatrogenic Withdrawal & Weaning Strategies
17 Chapter 17: Biostatistics & Study Design in Pediatric Research
17.1 Observational vs Experimental Pediatric Study Designs 17.2 Biostatistical Testing, Power & Sample Size in Small Pediatric Cohorts 17.3 Diagnostic Testing, Sensitivity, Specificity & Predictive Values
18 Chapter 18: Pediatric Evidence Appraisal, Regulatory Framework & Ethics
18.1 Pediatric Drug Legislation: BPCA, PREA & Labeling Nuances 18.2 Institutional Review Boards (IRB), Assent & Informed Consent in Minors 18.3 Evaluating Clinical Practice Guidelines & Formulating Off-Label Recommendations
19 Chapter 19: Pediatric Education, Health Literacy & Communication
19.1 Caregiver Health Literacy & Pediatric Medication Adherence 19.2 Interprofessional Education & Clinical Teaching Strategies 19.3 Developing Age-Appropriate Patient Educational Materials
20 Chapter 20: Pediatric Immunizations & Public Health Advocacy
20.1 ACIP Pediatric Immunization Schedule: Routine Childhood Vaccines 20.2 Adolescent Immunizations, Vaccine Hesitancy & Catch-Up Schedules 20.3 Pediatric Public Health Disparities & Special Population Advocacy
21 Chapter 21: Pediatric Practice Management — Laboratory Stewardship, Pharmacoeconomics & Informatics
21.1 Pediatric Laboratory Practices: Blood Conservation, Sampling Timing & Age-Specific Reference Intervals 21.2 Pharmacoeconomics, Formulary Management & Cost-Containment in Pediatrics 21.3 Clinical Informatics, CPOE Decision Support & Drug Shortage Management
13.2 Smart Infusion Pumps & Dose Error Reduction Systems (DERS)
Key Takeaways Explain This Topic AI
Smart infusion pumps equipped with Dose Error Reduction Systems (DERS) intercept up to 73% of intravenous programming errors by validating programmed rates, concentrations, and dosing units against predefined institutional safety boundaries.
The historical 'Rule of 6' ( 6 × weight in kg = mg in 100 mL 6 \times \text{weight in kg} = \text{mg in 100 mL} 6 × weight in kg = mg in 100 mL , running at 1 mL/h = 1 mcg/kg/min 1 \text{ mL/h} = 1 \text{ mcg/kg/min} 1 mL/h = 1 mcg/kg/min ) is obsolete and condemned by ISMP and ASHP; it has been universally replaced by Standardized Concentration Libraries to eliminate bedside calculation errors and fluid overload.
Clinical Care Areas (CCAs) tailor pump libraries to patient population physiology: NICU CCAs restrict flow rates to micro-infusion ranges (0.01–10 mL/h) with weight-based dosing (mcg/kg/min), whereas PICU and General Pediatric CCAs offer expanded concentration tiers and distinct rate parameters.
Soft limits provide clinician-overridable advisory alerts for justified off-protocol therapy, whereas Hard limits establish non-overridable, absolute boundaries that block lethal programming errors such as ten-fold overdoses (e.g., hard stop for continuous insulin >0.15 units/kg/h).
In neonatal micro-infusions (<0.5 mL/h), large syringes (50–60 mL) absorb pressure and delay occlusion alarms by 40–120 minutes; utilizing smaller syringes (10–20 mL) accelerates line pressure spikes to trigger occlusion alarms within 5–15 minutes while minimizing dead-space flushing bolus hazards.
Last updated: September 2026
13.2 Smart Infusion Pumps & Dose Error Reduction Systems (DERS)
Intravenous pharmacotherapy in neonatal and pediatric populations carries the highest risk of medication administration errors in hospital settings. The deployment of smart infusion pumps equipped with Dose Error Reduction Systems (DERS) represents one of the most effective technological interventions for intercepting programming mistakes. However, smart pumps are not autonomous safeguards; their efficacy depends entirely on rigorous drug library architecture, rational clinical care area (CCA) segmentation, standardized concentrations, strict limit configurations, and continuous quality improvement (CQI) data surveillance.
Dismantling the Historical "Rule of 6"
For decades, pediatric critical care medicine relied on the "Rule of 6" to calculate continuous infusions of vasoactive medications (e.g., dopamine, dobutamine, epinephrine, isoproterenol). Mass of Drug to Add (mg) = 6 × Patient Weight (kg) [ in 100 mL Diluent ] \text{Mass of Drug to Add (mg)} = 6 \times \text{Patient Weight (kg)} \quad [\text{in } 100 \text{ mL Diluent}] Mass of Drug to Add (mg) = 6 × Patient Weight (kg) [ in 100 mL Diluent ]
Under this mathematical convention, an infusion rate of 1 mL/hour 1 \text{ mL/hour} 1 mL/hour delivers exactly 1 mcg/kg/min 1 \text{ mcg/kg/min} 1 mcg/kg/min : 6 × Weight (mg) 100 mL = 6 , 000 × Weight (mcg) 100 mL = 60 × Weight mcg mL ⟶ 1 mL/h = 60 × Weight (mcg) 60 min = 1 mcg kg ⋅ min \frac{6 \times \text{Weight (mg)}}{100 \text{ mL}} = \frac{6,000 \times \text{Weight (mcg)}}{100 \text{ mL}} = 60 \times \text{Weight } \frac{\text{mcg}}{\text{mL}} \quad \longrightarrow \quad 1 \text{ mL/h} = \frac{60 \times \text{Weight (mcg)}}{60 \text{ min}} = 1 \frac{\text{mcg}}{\text{kg}\cdot\text{min}} 100 mL 6 × Weight (mg) = 100 mL 6 , 000 × Weight (mcg) = 60 × Weight mL mcg ⟶ 1 mL/h = 60 min 60 × Weight (mcg) = 1 kg ⋅ min mcg
Why the "Rule of 6" Has Been Condemned and Replaced
Although computationally convenient in an era before microchip-driven infusion pumps, the Rule of 6 is now recognized by ISMP, ASHP, and the American Academy of Pediatrics (AAP) as a profound source of medication error and patient harm :
Bedside Compounding Errors: Nurses or satellite technicians performed individualized mathematical calculations and manual dilution at the bedside, leading to frequent ten-fold dosing errors and sterility breaches.
Infusion Fluid Overload vs. Excessive Osmolality: In extremely low birth weight (ELBW) neonates, adding drug calculated by the Rule of 6 creates an extraordinarily dilute solution when running at low clinical rates, forcing excessive volume delivery in fluid-restricted infants. Conversely, in older, heavier children, the formula produces hyperosmolar solutions that cause rapid peripheral thrombophlebitis and extravasation tissue necrosis.
Barcoding and DERS Incompatibility: Because the resulting concentration varies with every single patient weight, commercial barcoded premixed bags cannot be used, and smart pump drug libraries cannot lock in standard concentrations.
ASHP Standardize 4 Safety Initiative: Modern practice mandates Standard Concentration Libraries . Hospitals stock standardized, fixed concentrations across pediatric populations (e.g., Epinephrine 16 mcg/mL and 64 mcg/mL; Dopamine 800 mcg/mL, 1600 mcg/mL, and 3200 mcg/mL; Fentanyl 10 mcg/mL and 50 mcg/mL). Smart pumps calculate the precise flow rate in mL/hour based on the patient's verified metric weight and desired weight-based dose. Comparison: Historical "Rule of 6" vs. Modern Standardized Concentrations:
- FEATURE RULE OF 6 (OBSOLETE) STANDARDIZED CONCENTRATIONS (CURRENT)
- ──────────────────────────────────────────────────────────────────────────────────────────────
- Concentration Variable (changes per patient) Fixed (1–3 standard institutional tiers)
- Compounding Location Bedside unit nursing staff Central IV cleanroom (USP <797>) or commercial
- Bar-Code Scanning (BCMA) Impossible (custom bag) Fully supported (manufacturer barcode)
- Smart Pump DERS Locking Cannot pre-program conc Pre-programmed concentration lines
- Fluid Overload Risk Extremely high in neonates Controlled via concentrated standard tiers
- Extravasation Risk Unpredictable osmolality Known, tested osmolar boundaries
- ──────────────────────────────────────────────────────────────────────────────────────────────
- Clinical Care Areas (CCAs)
A critical feature of DERS architecture is the segmentation of the master drug library into Clinical Care Areas (CCAs) . A neonate in the NICU has vastly different pharmacokinetic requirements, fluid tolerances, and hemodynamic vulnerabilities than a child on the general medical floor or an adolescent in the PICU.
Core Pediatric CCAs and Their Configurations
Neonatal Intensive Care Unit (NICU): Prioritizes micro-infusion rates (0.01 to 10 mL/hour), weight-based units exclusively (mcg/kg/min, mcg/kg/hour, units/kg/hour), strict volume-to-be-infused (VTBI) caps to prevent drowning small infants, and high-concentration tiers for severe fluid restriction.
Pediatric Intensive Care Unit (PICU): Features broader titratable ranges for inotropes, vasopressors, and sedatives; accommodates both peripheral and central-line concentration entries; supports rapid titration bolus allowances.
General Pediatric Ward: Completely eliminates high-potency inotropes (e.g., epinephrine, norepinephrine, milrinone) and neuromuscular blockers from the active pump library to prevent inadvertent selection in unmonitored units; restricts opioid infusions to low baseline parameters.
Pediatric Oncology / Bone Marrow Transplant: Incorporates specialized hydration protocols, high-dose electrolyte infusions, and specialized immunosuppressive agents (e.g., cyclosporine, tacrolimus) with custom titration rules. CCA Profile Segmentation in a Master Pediatric Drug Library:
- ┌──────────────────────────────────────────────────────────┐
- │ MASTER INSTITUTIONAL DRUG DATABASE │
- └────────────────────────────┬─────────────────────────────┘
- │
- ┌────────────────────────────┼─────────────────────────────┐
- ▼ ▼ ▼
- ┌─────────────────┐ ┌─────────────────┐ ┌─────────────────┐
- │ NICU CCA │ │ PICU CCA │ │ PEDS MED/SURG │
- ├─────────────────┤ ├─────────────────┤ ├─────────────────┤
- │ • Micro-rates │ │ • Expanded tiers│ │ • Inotropes │
- │ (0.01–10 mL/h)│ │ (central IV) │ │ LOCKED OUT │
- │ • Weight-based │ │ • Wide inotrope │ │ • Paralytics │
- │ units only │ │ titration │ │ LOCKED OUT │
- │ • Fluid-sparing │ │ • Post-op ECMO │ │ • Strict basal │
- │ standard conc │ │ configurations│ │ opioid caps │
- └─────────────────┘ └─────────────────┘ └─────────────────┘
- Soft Limits vs. Hard Limits
DERS establishes safety boundaries called dose limits around each medication entry in the pump library. These boundaries are divided into soft limits and hard limits.
1. Soft Limits (Advisory Warnings)
Soft Minimum: Warns the clinician that the programmed dose is unusually low, potentially subtherapeutic (e.g., fentanyl continuous infusion <0.5 mcg/kg/hour).
Soft Maximum: Alerts the clinician that the programmed dose exceeds typical practice guidelines. Clinicians can override a soft limit after reviewing the clinical justification and confirming patient identity and clinical status.
Clinical Utility: Accommodates legitimate clinical exceptions (e.g., escalating opioid infusions in opioid-tolerant oncology patients, high-dose epinephrine during refractory septic shock).
2. Hard Limits (Non-Overridable Stops)
Hard Minimum: A floor below which the pump cannot be programmed under any circumstance.
Hard Maximum: An absolute ceiling that cannot be overridden by the clinician . The pump refuses to initiate the infusion until the rate is reprogrammed within safe parameters.
Clinical Utility: Designed to block lethal ten-fold or hundred-fold calculation errors, decimal misplacements, or rate/dose field confusions (e.g., programming a 10-kg child for 100 mcg/kg/min of dopamine instead of 10 mcg/kg/min).
Medication & Dosing Unit Typical CCA Soft Minimum Soft Maximum Hard Maximum Rationale for Hard Maximum Cap
Epinephrine (mcg/kg/min) PICU 0.02 0.5 1.5 Doses > 1.5 mcg/kg/min >1.5 \text{ mcg/kg/min} > 1.5 mcg/kg/min cause severe peripheral necrosis, myocardial ischemia, and fatal tachyarrhythmias
Dopamine (mcg/kg/min) NICU / PICU 2.0 15.0 20.0 Doses > 20 mcg/kg/min >20 \text{ mcg/kg/min} > 20 mcg/kg/min cause extreme alpha-1 vasoconstriction, gangrene, and tachyarrhythmias
Regular Insulin (units/kg/h) PICU (DKA) 0.03 0.1 0.15 Doses > 0.15 units/kg/h >0.15 \text{ units/kg/h} > 0.15 units/kg/h cause precipitate osmolality drop, hypokalemia, and cerebral edema
Fentanyl (mcg/kg/h) PICU 0.5 3.0 5.0 Doses > 5 mcg/kg/h >5 \text{ mcg/kg/h} > 5 mcg/kg/h without acute titration indicate lethal programming error; causes severe rigidity and hypotension
Morphine (mcg/kg/h) Peds Floor 5.0 20.0 30.0 Prevents fatal opioid-induced respiratory depression on unmonitored general pediatric units
Potassium Chloride (mEq/kg/h) PICU 0.1 0.3 0.5 Infusions > 0.5 mEq/kg/h >0.5 \text{ mEq/kg/h} > 0.5 mEq/kg/h precipitate fatal hyperkalemic ventricular fibrillation and asystole
Pump Compliance Auditing & Override Analysis
The presence of smart pump hardware does not guarantee medication safety if clinicians routinely bypass the software. Safe healthcare systems maintain a Continuous Quality Improvement (CQI) surveillance program targeting smart pump data:
DERS Compliance Rate: The percentage of intravenous infusions initiated using the DERS drug library rather than using the generic, unprotected "Basic Infusion" mode. The national benchmark established by ISMP is ≥ 95 % \ge 95\% ≥ 95% compliance . Compliance rates below 90% indicate severe cultural, software, or workflow failure.
Root Causes of Basic Infusion Bypasses:
Emergent resuscitations where clinicians believe navigating library menus takes too long.
Missing drug or concentration entries in the pump library for specific clinical scenarios.
Incorrect weight entry blocks or confusing CCA menus.
Override Analysis and Alarm Fatigue:
Frequent soft-limit overrides signal that the library parameters are clinically unrealistic. For example, if PICU nurses override the soft maximum for dexmedetomidine (set at 0.7 mcg/kg/hour) in 80% of infusions because patient sedation routinely requires 1.0 to 1.4 mcg/kg/hour, the alert ceases to function as a safety warning. Instead, it breeds alarm fatigue , conditioning nurses to reflexively press "Confirm/Override" without reading.
Multidisciplinary pump committees (physicians, pediatric pharmacists, nursing leaders) must review quarterly CQI data to adjust soft limits to match clinical reality while maintaining unbreachable hard limits.
Neonatal Syringe Pump Mechanics & Delivery Precision
Neonatal intensive care units routinely deliver infusions at micro-rates ( < 0.5 mL/hour <0.5 \text{ mL/hour} < 0.5 mL/hour , and frequently 0.05 to 0.2 mL/hour 0.05 \text{ to } 0.2 \text{ mL/hour} 0.05 to 0.2 mL/hour in ELBW infants). Administering continuous infusions at these minute rates introduces extreme physical, hydraulic, and mechanical challenges. Syringe Size vs. Occlusion Alarm Latency at Micro-Infusion Rates (0.1 mL/h):
- 60-mL Syringe (Large Barrel Area): [=== Compliance & Tubing Expansion ===] ──► 60 to 120+ minutes
- (Massive dead space, delayed pressure buildup, delayed occlusion warning)
- 10-mL Syringe (Small Barrel Area): [== Rapid ΔP ==] ──► 5 to 15 minutes
- (Minimal dead space, rapid hydraulic pressure spike, immediate occlusion alarm)
- Syringe Size Selection Dynamics
The mechanical drive mechanism of a syringe pump utilizes a lead screw that advances a pusher block against the syringe plunger. At a rate of 0.1 mL/hour, the linear movement of the plunger is measured in fractions of a millimeter per hour:
Large Syringes (50–60 mL): Have a large cross-sectional surface area ( A A A ). Because pressure is force divided by area ( P = F / A P = F / A P = F / A ), generating enough fluid pressure to trigger the pump's downstream occlusion pressure sensor (typically set at 5 to 10 psi) requires significant linear force and volumetric compression. Furthermore, the compliance (elastic stretching) of the large plastic syringe barrel and IV administration tubing absorbs fluid volume before pressure rises. Consequently, when an intravenous line becomes completely occluded at 0.1 mL/hour 0.1 \text{ mL/hour} 0.1 mL/hour , a 60-mL syringe pump may fail to sound an occlusion alarm for 60 to 120 minutes or longer ! During this period, the critically ill neonate receives zero inotrope, leading to profound hemodynamic collapse.
Small Syringes (10–20 mL): Feature a much smaller cross-sectional diameter. The lead screw moves faster linearly to deliver the same volume, and hydraulic pressure builds rapidly upon occlusion. An identical line occlusion is detected within 5 to 15 minutes .
Practice Standard: For micro-infusion rates ( < 0.5 mL/hour <0.5 \text{ mL/hour} < 0.5 mL/hour ) in neonates, use the smallest syringe size compatible with the required volume and duration (typically 10-mL or 20-mL syringes).
Dead-Space Flushing Hazards
Intravenous extension tubing, stopcocks, needleless connectors, and catheter lumens contain an unmeasured volume of fluid termed dead space (ranging from 0.2 to 1.5 mL depending on the circuit):
Warning
If a continuous infusion of a potent vasoactive agent (e.g., epinephrine 16 mcg/mL) is running through an IV line at 0.1 mL/hour, the line contains concentrated drug throughout its entire dead space. If a nurse flushes that line with 1 to 2 mL of normal saline to clear a medication or administer an intermittent antibiotic, the entire dead-space volume of epinephrine is instantly bolused into the infant . In a 1-kg neonate, flushing a 0.5-mL dead space containing 16 mcg/mL epinephrine delivers an immediate 8 mcg bolus (8 mcg/kg) —an massive, lethal overdose causing intracranial hemorrhage, severe tachyarrhythmias, and death.
Critical Clinical Protections Against Flushing Disasters
Dedicated Lumen Policy: Vasoactive inotropes, concentrated sedatives, and paralytics must run through dedicated, single-purpose central line lumens that are never used for intermittent boluses or flushes.
Micro-Bore Low-Volume Tubing: Use specialized neonatal micro-bore extension sets with total internal priming volumes of < 0.1 mL <0.1 \text{ mL} < 0.1 mL .
Manifold Co-Infusion Proximity: When carrier fluids are required to maintain line patency (keep-vein-open / KVO), connect the inotrope infusion to the carrier line via a low-volume multi-port manifold placed as close as physically possible to the patient's vascular catheter hub .
Practice Pearls & BCPPS Exam Traps
Exam Trap 1: If an exam question asks how to resolve frequent clinician overrides of a smart pump soft limit in an ICU setting, the correct answer is not to convert the soft limit into a hard limit (which paralyzes patient care during emergencies) or to discipline nurses. The correct answer is to conduct CQI override analysis through a multidisciplinary committee and revise the drug library soft limit to reflect current clinical evidence.
Exam Trap 2: Remember that smaller syringes generate higher downstream pressure for a given lead-screw force ( P = F / A P = F / A P = F / A ). While smaller syringes provide faster occlusion alarms at micro-infusion rates, syringe pumps must be configured with appropriate pressure threshold settings to avoid false-positive alarms.
Standard Concentration Rule: The 'Rule of 6' is strictly obsolete on pediatric board examinations. Any answer choice recommending calculating bedside dilutions via the Rule of 6 is wrong. Standard concentrations are the universal standard of care.